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Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic urological condition
characterised by urinary urgency, frequency and pelvic pain, that significantly impacts
the quality of life for ∼5% of women. Bladder sensation is coordinated by primary
afferent sensory neurons that innervate the bladder wall, translating bladder stretch
into signals that travel to the brain via the spinal cord. Whilst the pathophysiology of
IC/BPS remains unknown, an increase in the permeability of the bladder urothelium
has been proposed as an initiating cause. Here we experimentally increased bladder
permeability and tracked bladder afferent sensitivity for up to 28 days. We found
that one day after increasing bladder epithelial permeability with in vivo bladder
infusion of protamine sulfate, mechanosensitive bladder afferents exhibited significant
hypersensitivity to bladder filling. This mechanical hypersensitivity was characterised
by significantly increased peak afferent firing rates and a decrease in the activation
threshold of individual afferents. Bladder afferent hypersensitivity occurred in the
absence of inflammation and changes in bladder muscle compliance, indicating a
direct sensitisation of peripheral afferent endings. Bladder afferent mechanosensitive
responses to distension returned to control levels by day 7 post-protamine sulfate
treatment and remained at control levels at 28-days post-treatment. Here we
demonstrate, contrary to the prevailing hypothesis, that increased bladder permeability
alone does not induce chronic bladder afferent sensitisation. Whilst experimentally
induced changes in bladder permeability are able to induce transient bladder
afferent hypersensitivity in the absence of inflammation, highly regulated homeostatic
mechanisms exist to rapidly repair the urothelial barrier and normalise bladder afferent
mechanosensitivity. Together, these data suggest that additional pathophysiology is
required to induce chronic bladder dysfunction.
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INTRODUCTION
Interstitial cystitis/bladder pain syndrome (IC/BPS), is a common
urological condition characterised by persistent or recurrent
chronic pelvic pain that is often accompanied by urinary urgency
and/or frequency (Grundy et al., 2018a; Akiyama et al., 2019).
Whilst the pathophysiology of IC/BPS has not been objectively
described and agreed upon, an increase in the permeability of the
bladder urothelium has been proposed as a potential cause of the
symptoms (Parsons, 2007; Keay et al., 2014; Hurst et al., 2015).
The bladder wall contains a dense network of afferent nerves
found both in the detrusor smooth muscle, and in close proximity
to the bladder lumen and urothelium (Kanda et al., 2016; Spencer
et al., 2018). These afferents respond directly to stretch, exhibiting
firing rates that closely encode intravesical pressure, and regulate
the autonomic circuits responsible for bladder storage (Fowler
et al., 2008; Grundy et al., 2019a,b). At greater bladder pressures,
these afferent signals progress to the cerebellum, providing
sensation and conscious control of bladder voiding (Fowler et al.,
2008; de Groat and Yoshimura, 2009). Whilst the urothelium has
been shown to exhibit sensory functions (Birder and Andersson,
2013), the primary role of the urothelium is to provide a
blood/urine barrier between the potentially toxic levels of urea,
ammonia, and other noxious metabolites found within the urine
and the underlying interstitium of the bladder (Lasič et al., 2015).
The considerable transcellular and paracellular
impermeability of the urothelial barrier is maintained
by tight junctions between luminally adjacent urothelial
cells, hydrophobic uroplakin plaques, and a substantial
glycosaminoglycan (GAG) mucus layer, that block the movement
of ions, solutes and toxic metabolites (Hurst et al., 2015; Lasič
et al., 2015; Grundy et al., 2018a). In a healthy bladder, these
components form the least penetrable epithelium found in
mammals (Lasič et al., 2015), however, a number of studies
have shown patients with IC/BPS have a diminished urothelium
or urothelial barrier (Parsons, 2007; Hurst et al., 2015). It has
therefore been hypothesised that in cases of increased urothelial
permeability, the myriad of noxious molecules contained within
the urine have direct access to the underlying sensory afferents
to induce neuronal hyperexcitability and induce exaggerated
sensation and bladder dysfunction (Parsons, 2007; Gonzalez
et al., 2014; Yoshimura et al., 2014). To further protect the
underlying structures of the bladder from increases in urothelial
permeability the urothelium consists of three cell layers. These
include a basal layer of cells located furthest from the bladder
lumen that includes stem cells responsible for the generation
and proliferation of new urothelium (Shin et al., 2011; Wang
et al., 2017). Partially differentiated intermediate cells are located
between the apical umbrella cells and the basal cells, providing
a reservoir of readily available replacement cells in the event of
umbrella cell damage or infection that provokes sloughing (Shin
et al., 2011; Hurst et al., 2015; Wang et al., 2017) and enables
rapid restoration of bladder impermeabiilty following damage.
In vivo bladder instillation of protamine sulfate is a commonly
used method for experimentally inducing bladder permeability
in the absence of overt bladder inflammation or significant
urothelial damage that returns to normal over a period of
3-7 days (Lavelle et al., 2002; Shin et al., 2011; Greenwood-Van
Meerveld et al., 2015).
It remains to be determined whether bladder permeability is
part of the initiating pathophysiology of bladder hypersensitivity
in IC/PBS patients or a downstream consequence of
inflammation that further exacerbates the condition. In this
study we sought to determine if chronic sensitisation of bladder
afferents could be induced by specifically increasing urothelial




12- to 16- week-old female C57BL/6J mice were used in this
study. The South Australian Health and Medical Research
Institute (SAHMRI) ethics committee approved all experiments
involving animals (animal ethics number SAM234). Mice
were acquired from an in-house C57BL/6J breeding program
(JAX strain #000664; originally purchased from The Jackson
Laboratory; breeding barn MP14; Bar Harbor, ME) within
SAHMRI’s specific and opportunistic pathogen-free animal care
facility. Prior to bladder infusion with either protamine sulfate
or vehicle (saline), mice were group housed (5 mice per cage)
in individual ventilated cages filled with chip coarse dust-
free aspen bedding (Cat#–ASPJMAEBCA; PuraBed, Niederglatt,
Switzerland). Mice had free access to LabDiet JL Rat and
Mouse/Auto6F chow (Cat#5K52, Jackson Laboratories, St. Louis,
MO) and autoclaved reverse osmosis water within a temperature-
controlled environment of 22◦C and a 12 hour light/12 hour
dark cycle. Following in vivo procedures, mice were individually
housed (1 mouse per cage) in individual ventilated cages. Mice
had an average weight of 21–23 g on the day of experimentation.
Ex vivo afferent recordings and myeloperoxidase (MPO) analysis
were performed on separate mice at 16 weeks of age.
Five groups of mice were used in this study. (1) mice that
received no treatment (Control: N = 5). (2) Mice that received
intrabladder infusion of saline and used 1 day later (1-day post
vehicle: N = 6). (3) Mice that received intrabladder infusion of
protamine sulfate and used 1 day later (1-day post PS: N = 5). (4)
Mice that received intrabladder infusion of protamine sulfate and
used 7 days later (7 days post PS: N = 5). (5) Mice that received
intrabladder infusion of protamine sulfate and used 28 days later
(28 days post PS: N = 6).
In vivo Infusion of Protamine Sulfate
The protamine sulfate model used was ostensibly as described
previously (Greenwood-Van Meerveld et al., 2015; Mohammadi
et al., 2018). These studies have shown that bladders from
protamine sulfate-treated animals showed signs of oedema at
1–5 days post infusion, but the urothelium remains intact with no
damage to the umbrella cells. Also, at 1 and 3 days post-infusion,
there are significant decreases in transepithelial electrical
resistance in protamine sulfate-treated urinary bladders which
normalises 5 days post-infusion (Greenwood-Van Meerveld
et al., 2015). In the current study, mice (12–16 weeks) were
Frontiers in Neuroscience | www.frontiersin.org 2 October 2020 | Volume 14 | Article 590871
fnins-14-590871 October 20, 2020 Time: 15:14 # 3
Grundy et al. Bladder Permeability Induces Afferent Hypersensitivity
anaesthetised (isoflurane 2%-4% in oxygen) and a lubricated
catheter (PE 50 tubing) was inserted into the urethra. Urine
was removed using a suction syringe, and a new lubricated
catheter (PE 50 tubing) was inserted. A fine silk suture was used
to tie around the catheter and the urethral opening to secure
the tube and to limit leakage of solution through the urethra
during infusion. The bladder was then infused with either 100 µl
of protamine sulfate (1 mg/ml) (Sigma-Aldrich) dissolved in
isotonic saline, or 100 µl of isotonic saline (vehicle) via a syringe.
Mice were maintained under anaesthetic for 10 minutes with
either the protamine sulfate or vehicle held within the bladder.
After 10 minutes, the bladder was drained via the syringe, the
syringe was removed and the mice were allowed to recover,
housed individually, and monitored twice daily for two days or
until mice were humanely killed (1, 7, or 28 days post procedure)
for use in bladder afferent recordings or in the myeloperoxidase
assay (Grundy et al., 2018c).
Ex Vivo Bladder Afferent Recordings
Bladder afferent nerve recordings were performed using an
ex vivo model previously characterised (Grundy et al., 2018b–d;
Grundy et al., 2020) on 16 week old mice that either did or did-
not (control mice) receive intrabladder infusion of protamine
sulfate or vehicle. Mice were humanely killed with CO2 and
dissected under a microscope with continual perfusion of gassed
(95% O2, 5% CO2) Krebs-bicarbonate solution (composition in
mmol/L: NaCl 118.4, NaHCO3 24.9, CaCl2 1.9, MgSO4 1.2, KCl
4.7, KH2PO4 1.2, glucose 11.7) at 35◦C. A catheter attached to
a syringe pump was inserted into the bladder via the urethra
to allow controlled distension at 100 µl/min with saline (0.9%).
A second two-way catheter was inserted into the bladder dome,
which is attached to a pressure transducer and an outflow tap,
enabling the recording of intravesical pressure during bladder
distension and the ability to passively drain the bladder after each
distension. Pelvic afferents, isolated from nerve fibres between
the pelvic ganglia and the spinal cord, were dissected into fine
multiunit branches and inserted into a glass electrode. Multiunit
afferent activity was detected by a Neurolog headstage (NL100,
Digitimer Ltd, United Kingdom), amplified, filtered (NL125,
band pass 300–4000 Hz) and captured by a computer via a
power 1401 interface and Spike 2 software (version 5.2.1, CED,
United Kingdom).
Experimental Protocol
A single nerve bundle was isolated for each experiment (N = 1 per
mouse) and inserted into the glass electrode during the dissection
process. This nerve bundle was used for the entire experiment
allowing multiunit afferent nerve recordings to be performed.
Bladder distensions (100 µl/min) were performed from 0 to
50 mmHg at 10-minute intervals until the afferent response to
distension was stable and reproducible.
Experimental Analysis
The raw nerve activity in ex vivo afferent recordings was
determined by the number of action potentials passing a pre-
set threshold (twice the background electrical level). This ensures
only mechanosensitive afferents are recorded. Each afferent nerve
contains a different number of single afferent units. In order
to identify individual units, single unit analysis was performed
offline by matching individual spike waveforms through linear
interpolation using Spike 2 software. Baseline afferent sensitivity
was determined by averaging the baseline nerve activity occurring
between distensions over a 5 minute period. Single afferent
units were characterised as previously described (Grundy et al.,
2019b). Briefly, afferent units were deemed ‘low threshold’ if the
pressure required to elicit continuous action potential firing was
16 mmHg or less. In contrast, ‘high threshold’ afferents exhibited
continuous action potential firing only when pressures exceed
18 mmHg (Grundy et al., 2019b; Grundy et al., 2020).
Myeloperoxidase (MPO) Assay
Bladders isolated from mice immediately following humane
euthanasia with CO2 were sectioned longitudinally, rinsed in
ice-cold PBS, and snap frozen in liquid nitrogen (Grundy
et al., 2018c). Tissue was defrosted on ice, weighed, and put
in 1.5 ml HTAB buffer (0.5% Hexadecyltrimethylammonium
bromide, pH6): 2.5 g HTAB (H5882, Sigma, Australia) added to
500 ml of 50 mM PBS, pH6). The tissue was then homogenised
with a cooled TissueLyserTM (Qiagen, Hilden, Germany) and
sonicated for 1 min. 20 µl of tissue homogenate was added
to 200 µl of an o-dianisidine dihydrochloride (o-dianisidine)
solution containing H2O2. Absorption data was recorded on
a VERSAmax 20 plate reader (Molecular Devices) at 450 nm
wavelength for 4 min with 30 sec interval-reading. All samples
were run in triplicates and a blank was included.
Analysis and Statistics
Data are expressed as Mean ± SEM. N equals the number
of animals, whilst n equals the number of individual afferents
identified using single unit analysis. Differences were considered
significant at a level of ∗P< 0.05, ∗∗P < 0.01,∗∗∗P < 0.001.
All data were analysed using GraphPad Prism 7 (San Diego,
CA, USA) in a blinded manner. For bladder afferent responses
to distension, compliance curves and multiunit and single unit
data was found to be normally distributed and analysed using
a two-way ANOVA with Tukey’s multiple comparisons. The
number of single units per experiment, activation thresholds,
peak afferent firing and MPO concentrations were analysed
by one-way ANOVA with Tukey’s multiple comparisons. The
specific tests used to analyse each data set and N numbers are
indicated within the individual figure legends.
RESULTS
As increases in the permeability or breakdown of the bladder
urothelium have commonly been associated with IC/BPS
symptoms, and it is known that bladder afferent sensory neurons
are located in close proximity to the urothelium (Spencer
et al., 2018), we hypothesised that the bladder hyperalgesia
occurring with increased urothelial permeability is via a
sensitisation of these afferent neurons to bladder distension.
To test this hypothesis, we performed ex vivo recordings from
bladder afferents (Figure 1). We compared bladder afferent
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FIGURE 1 | In vivo protamine sulfate treatment sensitises bladder afferent responses to distension. (A) One day after in vivo infusion of protamine sulfate (PS), but
not vehicle, bladder afferents exhibit significant hypersensitivity to bladder distension (N = 5–6 mice, *P < 0.05, **P < 0.01, Two-way ANOVA with Tukey’s multiple
comparisons post hoc test). Bladder afferent mechanosensitivity is normalised at seven days post PS infusion and is maintained at control levels 28 days after PS
infusion (N = 5–6 mice, ns P > 0.05, Two-way ANOVA with Tukey’s multiple comparisons post hoc test). (B) Total afferent area under the curve (AUC) is a summation
of peak afferent firing from each 5 mmHg pressure increment from 0–50 mmHg. Total afferent AUC is significantly elevated one day after in vivo infusion of protamine
sulfate (PS), but not after vehicle treatment (N = 5–6 mice, *P < 0.05, **P < 0.01, One-way ANOVA with Tukey’s multiple comparisons post hoc test). (C) Example
experimental traces showing bladder afferent firing, intravesical pressure, and raw nerve activity to repeated distensions with saline (i) 1 day after bladder infusion
with vehicle and (ii) 1 day after bladder infusion with protamine sulfate. Afferent responses to distension (0–50 mmHg) are stable and reproducible. (D) Spontaneous
baseline afferent responses (N = 5–6 mice, ns P > 0.05, One-way ANOVA with Tukey’s multiple comparisons post hoc test). (E) The compliance (pressure/volume
relationship) of the bladder muscle during graded bladder distension is not significantly altered following intra-bladder infusion of PS or vehicle (N = 5–6 mice,
nsP > 0.05, Two-way ANOVA with Tukey’s multiple comparisons post hoc test).
mechanosensitivity from mice 1 day after in vivo instillation of
vehicle with mice 1, 7, and 28 days after in vivo instillation of
protamine sulfate. We observed a significant increase in bladder
afferent mechanosensitivity from bladders 1 day after protamine
sulfate treatment, but no change in mechanosensitivity from
mice receiving the sham vehicle infusion (Figures 1A-C). Only
low levels of spontaneous bladder afferent firing were observed
in the periods between bladder distension (Figure 1C) and
this was not found to be significantly altered following vehicle
or protamine sulfate treatment (Figure 1D). The increase in
bladder afferent mechanosensitivity we observed at 1-day post
protamine sulfate treatment occurred in the absence of changes
in muscle compliance (pressure/volume relationship; Figure 1E),
indicating that the effects of protamine sulfate on afferent
mechanosensitivity are not secondary to changes in muscle
function. Intriguingly, the bladder afferent hypersensitivity to
graded distension that was observed 1-day post protamine
sulfate returned to control levels at day 7 post treatment and
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was maintained at control levels up to 28 days post treatment
(Figures 1A–E). These data therefore indicate that protamine
sulfate induced urothelial permeability induces only transient
afferent hypersensitivity.
Post hoc single-unit analysis of multiunit bladder afferent
recordings allows for a more comprehensive understanding
of the entire mechanosensitive response. Upon grouping all
single afferent units from each experimental cohort together, we
found the same pattern of response as seen in our multiunit
afferent responses (Figure 1), with a significant increase
in mechanosensitivity during the course of graded bladder
distension (Figure 2A). Additionally, when we analysed the peak
afferent response to bladder distension (0-50 mmHg) from each
individual afferent unit we discovered that afferents recorded at
1-day post protamine sulfate exhibited a significant increase in
the peak firing frequency (Figure 2B). Furthermore, analysing
this data further shows us that whilst the lowest peak afferent
firing in mice 1-day post protamine sulfate is 7 imp/s, in the other
experimental cohorts, a large proportion of units exhibit peak
firing frequencies between 2-7 imp/s (Figure 2B). To identify
if the transient increases in afferent firing following protamine
sulfate treatment were due to the recruitment of an additional
cohort of afferents (silent afferents), as has been identified in the
presence of inflammatory mediators (Michaelis et al., 1996; Prato
et al., 2017; Grundy et al., 2020), we compared the number of
individual single units identified by spike waveform analysis per
experiment. We found no significant difference in the number
of single units per experiments between experimental cohorts
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FIGURE 2 | Single unit bladder afferent mechanosensitivity. (A) One day after in vivo infusion of protamine sulfate (PS), but not vehicle, single bladder afferent units
exhibit hypersensitivity to bladder distension (n = 41–48 individual units from N = 5–6 mice, #P < 0.05, Two-way ANOVA with Tukey’s multiple comparisons post hoc
test). Single unit bladder afferent mechanosensitivity is unchanged at seven days post PS infusion and is maintained at control levels 28 days after PS infusion
(n = 31–49 individual units N = 5–6 mice, ns P > 0.05, Two-way ANOVA with Tukey’s multiple comparisons post hoc test). (B) Peak single unit afferent responses to
bladder distension (0–50 mmHg) are significantly elevated one day after PS infusion compared to control, One day post vehicle, and seven and 28 days post PS
(n = 31–49 individual units from N = 5–6 mice, **P < 0.01,***P < 0.05, one-way ANOVA with Tukey’s multiple comparisons post hoc test). Peak firing of each
individual unit is * represented by a single dot. Dashed line represents least responsive units in 1-day PS group. (C) The mean number of single units differentiated by
spike sorting software in each individual multiunit nerve recording experiment (N = 5–6 mice). (D) The activation threshold of individual afferent units is significantly
reduced one day after in vivo PS but not vehicle infusion (n = 31–49 individual units from N = 5–6 mice, *P < 0.05, one-way ANOVA with Tukey’s multiple
comparisons post hoc test).
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(Figure 2C). In addition to an increase in mechanosensitive
bladder afferent firing frequency 1-day after protamine sulfate
treatment, we also found single units exhibit significantly reduced
activation thresholds to bladder distension compared to control
and 7-days after protamine sulfate (Figure 2D), thus firing the
first train of action potentials at lower distension pressures.
In both our multiunit afferent recordings and following
post hoc single unit analysis, we observed an overall sensitisation
of mechanosensitive afferents 1-day after protamine sulfate
infusion, but not vehicle, that was most obvious above 20 mmHg
bladder distension (Figures 1, 2). In order to investigate this
further, we distinguished functional subpopulations of low- and
high-threshold mechanosensitive units by activation thresholds
as previously described (Grundy et al., 2019b) (Figures 3, 4).
When we dissect apart these single units, it becomes clear
that not all units are equally sensitive to changes in bladder
permeability. At 1-day post-protamine sulfate, low-threshold
units exhibited hypersensitivity to graded bladder distension
(Figure 3A) and an increase in the peak afferent response to
distension (Figures 3B,C). Overall, there were no significant
changes in the number of low-threshold afferents per experiment
(Figures 3D i–iii). In contrast to low-threshold afferents, the
mechanosensitivity of high-threshold afferents was relatively
unaffected by protamine sulfate (Figure 4A) and did not increase
the peak afferent response to distension (Figures 4B,C). There
were also no significant changes in the number of high-threshold
afferents, but there was a trend toward a decrease in the total
number and proportion of afferent units that could be classified as
high threshold at 1-day post-protamine sulfate (Figures 4D i–iii).
To confirm that the changes in bladder afferent
mechanosensitivity we observed in response to protamine
sulfate infusion were not due to the induction of inflammation,
a known inducer of neuronal hypersensitivity (de Groat and
Yoshimura, 2009), we measured myeloperoxidase (MPO)
activity in bladders isolated from each cohort of mice (Figure 5).
Overall, we found that neither the sham procedure (vehicle) nor
protamine sulfate infusion had a significant effect on bladder
MPO, indicating an absence of overt inflammation at the
time points tested.
DISCUSSION
Bladder afferent input into the central nervous system is
required for normal bladder function, regulating the autonomic
circuits that prompt detrusor relaxation during storage,
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FIGURE 3 | Low-threshold bladder afferent responses following in vivo protamine sulfate treatment. (A) Low-threshold bladder afferent mechanoreceptors exhibit
significant hypersensitivity to bladder distension one day after in vivo infusion of protamine sulfate (PS) but not vehicle (n = 21–38 individual units from N = 5–6 mice,
#P < 0.05, Two-way ANOVA with Tukey’s multiple comparisons post hoc test). (B) Example experimental trace showing a single low-threshold afferent unit in
response to graded bladder distensions with saline (0–50 mmHg). Dashed line represents distinction of activation thresholds between low- and high- threshold units
(16 mmHg). Individual units are determined by color spike profile (insert). (C) Peak afferent response of low-threshold bladder afferents to distension (*P < 0.05,
**P < 0.01, **P < 0.001, One-way ANOVA with Tukey’s multiple comparisons post hoc test). (D) (i) The percentage of single afferent units classified as low-threshold
(LT) per experiment, (ii) the total number of units classified as low-threshold (LT), and (iii), low-threshold units (LT) as a percentage of the total number of
mechanosensitive units in each experimental cohort.
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FIGURE 4 | High-threshold bladder afferent responses following in vivo protamine sulfate treatment. (A) High-threshold bladder afferent mechanoreceptors exhibit
moderate hypersensitivity to bladder distension one day after in vivo infusion of protamine sulfate but not vehicle (PS) (n = 4–13 individual units from N = 5–6 mice,
#P < 0.05, Two-way ANOVA with Tukey’s multiple comparisons post hoc test). (B) Example experimental trace showing a single high-threshold afferent unit in
response to graded bladder distensions with saline (0–50 mmHg). Dashed line represents distinction of activation thresholds between low- and high- threshold units.
Activation threshold is determined as the pressure from which a continuous train of action potentials occurs. Individual units are determined by color spike
profile (insert). (C) Peak afferent response of high-threshold bladder afferents to distension (ns, P > 0.05. One-way ANOVA with Tukey’s multiple comparisons
post hoc test). (D) (i) The percentage of single afferent units classified as high-threshold (HT) per experiment, (ii) the total number of units classified as high-threshold
(HT), and (iii), high-threshold units (HT) as a percentage of the total number of mechanosensitive units in each experimental cohort.
and initiating urge sensations necessary for the conscious
control of voiding (Fowler et al., 2008). As the degree of
bladder afferent input into the central nervous system is
correlated both to the intensity of sensation and autonomic
output controlling the micturition reflex, an increase in
bladder permeability and the corresponding increase in
afferent firing has the potential to translate to the sensory
symptoms of urgency, frequency and pelvic pain associated
with IC/BPS (Fowler et al., 2008; de Groat and Yoshimura,
2009; Yoshimura et al., 2014). Accordingly, preclinical models
of bladder inflammation and infection that induce changes in
the intensity of bladder afferent signalling have been correlated
with bladder dysfunction (de Groat and Yoshimura, 2009;
Grundy et al., 2018a).
There is considerable evidence that the pathophysiology
of IC/BPS incorporates an increase in urothelial permeability
(Hurst et al., 2015). Numerous studies, both clinical and pre-
clinical, have provided evidence of urothelial abnormalities
in IC/BPS (Parsons, 2007; Hurst et al., 2015). However,
delineating bladder permeability from bladder inflammation,
as well as cause and effect, has proved challenging (Grundy
et al., 2019a). Inflammation is a well-known regulator of
neuronal excitability (Grundy et al., 2018a), and our aim was
to investigate only the role of increasing bladder permeability
in bladder afferent sensitisation. To achieve this, we used
a brief intrabladder infusion of 1 mg/ml protamine sulfate
to induce bladder permeability. Whilst we didn’t specifically
demonstrate this in the current study, this concentration has
previously been shown to induce bladder permeability without
overt bladder inflammation or urothelial damage (Lavelle et al.,
2002; Shin et al., 2011; Greenwood-Van Meerveld et al.,
2015). Protamine sulfate promotes an increase in bladder
permeability by inactivating the sulphated polysaccharides of
the GAG layer, increasing transcellular permeability of the
urothelium and thus increasing absorption of urine solutes
(Lasič et al., 2015). Crucially, in this study we confirmed
that neither protamine sulfate nor vehicle treatment induced
bladder inflammation by quantifying myeloperoxidase (MPO),
a key local mediator of tissue damage and inflammation
(Aratani, 2018) used to quantify bladder inflammation in
both pre-clinical and clinical samples (Oottamasathien et al.,
2011; Ciragil et al., 2014). Overall, we show that in vivo
bladder infusion of protamine sulfate significantly enhances
bladder afferent mechanosensitivity to graded distension in the
absence of inflammation. These data provide the first direct
evidence for a role of bladder permeability in regulating bladder
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FIGURE 5 | Protamine sulfate does not induce overt bladder inflammation.
In vivo bladder infusion with protamine sulfate or vehicle has no effect on
bladder myeloperoxidase (MPO) concentrations at 1, 7, or 28 days post
infusion (N = 5–8 mice, ns P > 0.05, One-way ANOVA with Tukey’s multiple
comparisons post hoc test).
mechanosensation. However, we identify that this neuronal
hyperexcitability is transient, with bladder afferent responses
returning to control levels within 7 days after protamine sulfate
treatment. We also show that bladder afferent responses are
maintained at control levels 28-days post-protamine sulfate,
suggesting secondary hypersensitivity is not occurring in
these conditions.
A number of previous studies have provided indirect evidence
that changes in bladder permeability can induce sensory
dysfunction (Keay et al., 2014; Hurst et al., 2015; Grundy et al.,
2018a; Mohammadi et al., 2018), however, it remained to be
determined if bladder permeability is part of the underlying
pathology of visceral hypersensitivity disorders such as IC/BPS,
or an unavoidable consequence of inflammation (Grundy et al.,
2019a). Our data show that increasing bladder permeability
with protamine sulfate in the absence of inflammation induces
hypersensitivity of bladder afferents to graded bladder distension.
It is likely these changes in bladder afferent sensitivity are
responsible for the pelvic sensitivity observed in response to
suprapubic stimulation following protamine sulfate treatment
(Mohammadi et al., 2018). We also observed increased peak
firing of single units 1-day after protamine sulfate treatment, as
well as a trend toward decreased afferent activation thresholds
and an increase in the ratio of low-threshold afferents. We
did not observe an increase in the number of mechanosensory
single units per experiment in any of the experimental groups,
indicating that ‘silent afferents’ were not recruited by protamine
sulfate treatment. Silent afferents represent a functionally distinct
subclass of bladder afferents that have traditionally been recruited
to become mechanosensitive in the presence of inflammatory
stimuli (Habler et al., 1990; Dmitrieva and McMahon, 1996;
Grundy et al., 2020; Guo et al., 2020). The lack of silent
afferent recruitment here further supports our hypothesis
that protamine sulfate-induced hypersensitivity is functionally
distinct from inflammatory-induced hypersensitivity. Together
these data indicate that increasing bladder permeability is
able to potentiate the mechanosensory signal conveyed to the
spinal cord during bladder distension and that this effect at
this concentration of protamine sulfate (1 mg/ml) is transient.
Whilst we did not investigate the precise mechanism driving
bladder afferent sensitivity in this study, it is likely that as
urothelial permeability is increased, urinary contents gain access
to afferent nerves to either cause afferent hypersensitivity directly,
or indirectly via actions on urothelial cells. We and others
have shown that a variety of endogenous mediators can activate
bladder afferents, causing afferent hypersensitivity (de Groat
and Yoshimura, 2009; Birder and Andersson, 2013; Yoshimura
et al., 2014; Grundy et al., 2018b; Konthapakdee et al., 2019;
Grundy et al., 2020).
Interestingly, a previous study using 5x the concentration
of protamine sulfate demonstrated that visceromotor responses
(VMR) to bladder distension were actually reduced at 1-
day post infusion (Stemler et al., 2013). This particular
study showed the reduction in VMR was associated with a
decrease in bladder expression of the pro-inflammatory/pro-
nociceptive cytokine IL-1ß and an increased expression of
the anti-inflammatory cytokine IL-4. The authors also suggest
that the bladder injury induced by the higher concentration
of protamine sulfate could increase the renewal mechanisms
originating from transient amplifying regulation rather than
urothelial stem cell activation (Stemler et al., 2013). As
afferent sensitisation is a balance between pro- and anti-
nociceptive mechanisms (Brierley and Linden, 2014; Sadeghi
et al., 2018; Grundy et al., 2019a), the Stemler study, at 5x
the concentration of protamine sulfate, may have recruited
more anti-nociceptive mechanisms than we have seen in
our current study.
Interestingly in our study, and in contrast to the proposed
hypothesis that changes in bladder permeability are an initiating
factor in the development of IC/BPS (Parsons, 2007), the bladder
afferent response to distension returned to control levels by day
7 after protamine sulfate treatment. As inflammation was not
present within the bladder, we hypothesise that this recovery was
due to rapid repair of the urothelial barrier. The urothelium has
the tightest epithelial barrier of all mammalian epithelial barriers
(Lasič et al., 2015), necessary for the maintenance of the blood-
urine barrier and compartmentalisation of the toxic constituents
of urine within the bladder during storage. Under normal
conditions, urothelial cells have an extremely slow turnover
rate (Birder and de Groat, 2007), however, following injury
or infection, the urothelium undergoes rapid injury-induced
proliferation of urothelial stem cells to restore the tight epithelial
barrier (Shin et al., 2011; Wang et al., 2017). Indeed, studies using
either the same or higher concentrations of protamine sulfate
as in our experiments have shown that the barrier function of
the urothelium is restored within 2-5 days after injury (Lavelle
et al., 2002; Greenwood-Van Meerveld et al., 2015). These data
thus indicate that transient increases in bladder permeability,
such as in this study, are unable to induce a protracted state
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of bladder permeability or bladder afferent hypersensitivity.
Given that IC/BPS is chronic in nature, our data suggests that
additional pathophysiology, or repeated insults to the bladder, are
required to induce long term neuroplasticity and the induction
of chronic afferent hypersensitivity necessary for sensory and
urological dysfunction (de Groat and Yoshimura, 2009; Grundy
et al., 2018a). Indeed, a positive feedback mechanism has been
proposed to exist, incorporating urothelial barrier disruption,
inflammation, and neuronal hyperexcitability in the induction of
IC/BPS (Gonzalez et al., 2014; Yoshimura et al., 2014). A role for
inflammation in mediating bladder afferent hyperexcitability is
well established (Yoshimura et al., 2014; Montalbetti et al., 2017;
Grundy et al., 2018a; Grundy et al., 2019a), and a number of pre-
clinical studies have shown that inflammation is able to induce
urothelial permeability (Lavelle et al., 1998; Eichel et al., 2001;
Grundy et al., 2018a; Grundy et al., 2019a). Therefore, our data
supports a mechanism whereby chronic bladder permeability is
likely a downstream consequence of inflammation, that provides
an addition degree of neuronal sensitisation.
CONCLUSION
Our data indicate that whilst changes in bladder permeability are
able to induce transient bladder afferent hypersensitivity, highly
regulated homeostatic mechanisms exist in a murine model to
rapidly repair the urothelial barrier, and as such, it is unlikely
that changes in permeability alone are the initiating factor in the
development of bladder disorders such as IC/BPS.
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